Jan 31 (Reuters) - Israel-based Teva Pharmaceutical Industries said on Wednesday it plans to divest its active pharmaceutical ingredient (API) business to focus on other growing markets.
The company expects the intended divestiture to be completed in the first half of 2025. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)
